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PRMT3, a protein arginine methyltransferase, has
been shown to influence ribosomal biosynthesis by
catalyzing the dimethylation of the 40S ribosomal
protein S2. Although PRMT3 has been reported to
be a cytosolic protein, it has been shown to meth-
ylate histone H4 peptide (H4 1–24) in vitro. Here,
we report the identification of a PRMT3 inhibitor
(1-(benzo[d][1,2,3]thiadiazol-6-yl)-3-(2-cyclohexeny-
lethyl)urea; compound 1) with IC50 value of 2.5 mMby
screening a library of 16,000 compounds using H4
(1–24) peptide as a substrate. The crystal structure
of PRMT3 in complex with compound 1 as well as
kinetic analysis reveals an allosteric mechanism of
inhibition. Mutating PRMT3 residues within the allo-
steric site or using compound 1 analogs that disrupt
interactions with allosteric site residues both abro-
gated binding and inhibitory activity. These data
demonstrate an allosteric mechanism for inhibition
of protein arginine methyltransferases, an emerging
class of therapeutic targets.
INTRODUCTION
Epigenetic regulation of gene expression, includingmechanisms
dependent on histone methylation, have been implicated in a
variety of diseases including cancer (Albert and Helin, 2010;
Kelly et al., 2010; Nimura et al., 2010; Vallance and Leiper,
2004; Yoshimatsu et al., 2011). Protein lysine (PKMT) and protein
arginine (PRMT) methyltransferases catalyze the transfer of a
methyl group from S-adenosyl-L-methionine (SAM) to lysine or
arginine residues on histone tails, respectively, and in many
cases also methylate non-histone proteins (Dhayalan et al.,
2011; Huang et al., 2010; Liu et al., 2011; Pagans et al., 2010;
Shi et al., 2007). These two families of proteins are distinguish-
able by the primary sequence of their catalytic domains andStructure 20, 1425three-dimensional structures (Campagna-Slater et al., 2011;
Copeland et al., 2009). Nine different human protein arginine
methyltransferases (PRMTs) have been identified and classified
into different subtypes. Type I PRMTs, such as PRMT1, PRMT2,
PRMT3, PRMT4 (CARM1), PRMT6, and PRMT8, transfer two
methyl groups to a single nitrogen atom of the guanidine moiety
of arginine (asymmetric dimethylation). Type II PRMTs, such as
PRMT5, transfer two methyl groups to two different nitrogen
atoms of the guanidine (symmetric dimethylation). PRMT7
was found to monomethylate various substrates (Bedford and
Richard, 2005; Di Lorenzo and Bedford, 2011) and recently, Zur-
ita-Lopez et al. confirmed that PRMT7 only monomethylates
its substrates and it is not capable of catalyzing dimethylation
(a type III enzyme) (Zurita-Lopez et al., 2012). Arginine residues
2, 8, 17, and 26 of histone H3 and arginine 3 of H4 are substrates
for PRMTs.
PRMT3 is a type I PRMT and has been shown to be a cytosolic
protein. A 29 kDa protein was originally reported as a substrate
for PRMT3 (Tang et al., 1998), which was later identified as
40S ribosomal protein S2 (rpS2) in yeast (Bachand and Silver,
2004) and mammalian cells (Swiercz et al., 2005). PRMT3 meth-
ylates rpS2, resulting in stabilization, and plays a role in proper
maturation of the 80S ribosome (Bachand and Silver, 2004; Di
Lorenzo and Bedford, 2011; Swiercz et al., 2005). Methylation
of rpS2 is conserved from yeast to human and influences ribo-
somal biosynthesis while pre-rRNA processing occurs normally
(Bachand and Silver, 2004; Swiercz et al., 2005, 2007). Cells
lacking PRMT3 have been reported to show accumulation of
free 60S ribosomal subunits and an imbalance in the 40S:60S
free subunit ratio. PRMT1 and PRMT3 have been reported to
methylate the recombinant mammalian nuclear poly(A)-binding
protein (PABPN1) which carries 13 asymmetrically dimethylated
arginine residues in its C-terminal domain (Fronz et al., 2008;
Smith et al., 1999; Tavanez et al., 2009). PRMT3 function has
been reported to be essential for dendritic spine maturation in
rats (Miyata et al., 2010). It also methylates a histone peptide
(H4 1–24) in vitro (Allali-Hassani et al., 2011). Histone H4R3 is
a modification associated with an increase in transcription of
a number of genes, including those under control of estrogen
receptor a and androgen receptor (Herrmann et al., 2009;–1435, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1425
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Figure 1. Compound 1 Is a Potent Inhibitor of PRMT3 Activity
(A) Crystal structure of compound 1 was determined and indicated that the
compound is 1-(benzo[d][1,2,3]thiadiazol-6-yl)-3-(2-cyclohexenylethyl)urea.
(B) Compound 1 inhibits the activity of PRMT3 at a balanced condition with
IC50 of 2.5 ± 0.1 mM as determined by SAHH-coupled assay.
See also Figures S1 and S2 and Table S2. Data points are presented as mean
values ± SD from three experiments.
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An Allosteric Inhibitor of PRMT3Obianyo et al., 2011; Wagner et al., 2006). Interestingly,
the tumor suppressor DAL-1/4.1B interacts with PRMT3 and
inhibits its protein argininemethyltransferase activity, suggesting
that DAL-1/4.1B may affect tumor growth by regulating protein
arginine methylation (Singh et al., 2004).
The critical roles of protein methyltransferases (PMTs) in a
variety of biological processes (Guccione et al., 2007; Hyllus
et al., 2007; Iberg et al., 2008; Pawlak et al., 2000; Yadav et al.,
2003) and diseases suggest that many of these enzymes may
be targets for a new generation of therapeutics (Frietze et al.,
2008; Hong et al., 2004; Kelly et al., 2010; Richon et al.,
2011). Within the last few years, efforts to identify inhibitors of
PRMTs have led to the identification of a number of compounds
with low or submicromolar IC50 values for CARM1 and PRMT1
(Allan et al., 2009; Bissinger et al., 2011; Cheng et al., 2011;
Huynh et al., 2009; Obianyo et al., 2011; Purandare et al.,
2008; Therrien et al., 2009; Wan et al., 2009). CARM1 has been
shown to be upregulated during the progression of prostate
cancer (Hong et al., 2004) and in breast tumors (El Messaoudi
et al., 2006). PRMT1 and PRMT3 are overexpressed in human
myocardial tissues from patients with coronary disease (Chen
et al., 2006) and have been implicated in oculopharyngeal
muscular dystrophy (OPMD) (Tavanez et al., 2009). Polyalanine
expansion in PABPN1 causes OPMD (Brais et al., 1998).
PRMT1 and PRMT3 are reported to be more associated with
expanded PABPN1 than normal PABPN1 and are found in intra-
nuclear inclusions formed by deposition of PABPN1 fibrils (Tava-
nez et al., 2009). Here, we report the discovery of 1-(benzo[d]
[1,2,3]thiadiazol-6-yl)-3-(2-cyclohexenylethyl)urea (compound 1),
a selective allosteric inhibitor of PRMT3, suggesting a possi-
ble novel mechanism for targeting PRMTs in general. The
structure of PRMT3 in complex with compound 1 along with
characterization of PRMT3 mutants reveals the mechanism
of selective allosteric inhibition and will be useful in further
development of more potent and cell active PRMT3 inhibitors.
RESULTS
Identification of Compound 1 as a PRMT3 Inhibitor
To identify inhibitors of PRMT3 activity, we screened truncated
PRMT3 (residues 211–531) against a library of sixteen thousand
diverse drug-like compounds (Supplemental Experimental Pro-
cedures) using a histone peptide (histone 4, residues 1–24)
as a substrate. The primary screen was performed using
a SAHH (S-adenosylhomocysteine hydrolase)-coupled assay
(Allali-Hassani et al., 2011) at peptide and SAM concentrations
of 2- and 5-fold above the Km for each substrate, respectively.
The most potent hit, compound 1 (1-(benzo[d][1,2,3]thiadiazol-
6-yl)-3-(2-cyclohexenylethyl)urea), had an IC50 value of 2.5 ±
0.1 mM (Hill Slope of 1.5) at peptide and SAM concentrations
equivalent to their respective Km values (Figure 1). Compound
1 also inhibited the commercially available full length PRMT3
with an IC50 value of 1.6 ± 0.3 mM (Hill Slope of 0.99; Figure S1
available online). Compound 1 had no inhibitory effect on
SAHH activity, or other components of the assay and direct
binding of compound 1 to PRMT3 was confirmed by surface
plasmon resonance (SPR) (Figure 2). Compound 1 exhibited
rapid on and off rates with a KD value of 9.5 ± 0.5 mM as deter-
mined by steady state analysis. In similar experiments the pres-1426 Structure 20, 1425–1435, August 8, 2012 ª2012 Elsevier Ltd Alence of 100 mM SAM did not affect the KD value of compound 1
(7 ± 0.7 mM). KD values for SAM in the presence of 20 mM and
absence of compound 1 (55 ± 0.8 and 59 ± 7 mM, respectively)
were not significantly different either, indicating that SAM and
compound 1 are not competing for binding to PRMT3. Kinetic
analysis indicated that compound 1 is a noncompetitive inhibitor
of PRMT3 activity with respect to both SAM and peptide
substrates with Ki values of 2.9 ± 0.1 and 4.2 ± 1.1 mM, respec-
tively (Figure 3). We also assessed the inhibitory effect of
compound 1 on activity of PRMT3 using rpS2 as a substrate.
We expressed and purified recombinant rpS2 and determined
the kinetic parameters (Figures 4A and 4B). PRMT3 catalyzed
the methylation of rpS2 with a kcat value of 0.1 min
1 and Km
values of 1 ± 0.5 mM and 34 ± 1 mM for rpS2 and SAM, respec-
tively. The activity of PRMT3 was linear at the Km of both
substrates (Figure 4C) and was inhibited by compound 1 with
an IC50 value similar to that determined for the histone substrate
(2 ± 0.5 mM; Figure 4D).
Selectivity of compound 1 for PRMT3 was assessed by
screening against protein lysine methyltransferases G9a,
EHMT1, SUV39H2, SETD7, and SETD8 using the same
SAHH-coupled assay and protein arginine methyltransferases
PRMT1, PRMT4, PRMT5, and PRMT8 using a radioactivity-
based assay (Figure S2). Inhibition of the full-length PRMT3
was also performed using the radioactivity-based as describedl rights reserved
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Figure 2. Binding of Compound 1 Was Confirmed by SPR
(A) The subtracted sensorgram (fc3-fc1) of the duplicate compound 1 samples
showing blanks and compound cycles from aBiacore T200 single cycle kinetic
run. The compound concentrations are 1.25, 2.5, 5, 10, and 20 mM,with 60 s on
and off times.
(B) The duplicate binding curves that were used to calculate the KD and RMax
values for the compound 1-PRMT3 interaction are shown.
Structure
An Allosteric Inhibitor of PRMT3in the material and methods. All reactions were performed in
the linear range at substrate and SAM concentrations equivalent
to their respective Km values for each enzyme. Compound 1
showed no inhibitory activity on any of the PKMTs, which have
a very different overall protein conformational fold compared to
the PRMTs. Similarly, PRMT1, PRMT4, or PRMT8 (those closest
in sequence to PRMT3; 35%–51% amino acid sequence iden-
tity) were not inhibited by compound 1, while PRMT5 was very
weakly inhibited. In addition, we cannot rule out the possibility
of inhibition against more distantly related methyltransferases
(<20% sequence identity), such as SPOUT RNA methyltrans-
ferases (Petrossian and Clarke, 2011).
Compound 1 Binds in a Novel PRMT-Specific Allosteric
Pocket
To better understand the mechanism of action of compound 1,
the compound was cocrystallized with PRMT3 and the structure
was determined to 2.0 A˚ resolution (PDB ID: 3SMQ; Table 1). The
complex structure revealed that the compound binds in a
pocket distinct from both the SAM and substrate peptide bind-
ing pockets. Inhibitor-bound PRMT3 adopts a canonical PRMT
dimeric structure, previously described for rat PRMT3, PRMT1,
and CARM1 (Troffer-Charlier et al., 2007; Yue et al., 2007; ZhangStructure 20, 1425and Cheng, 2003; Zhang et al., 2000) (Figure S3): each monomer
is composed of a cofactor binding domain structurally related to
the SAM-dependent methyltransferase fold, a barrel-like domain
that may contribute to recruitment of substrate, and a helical
dimerization arm that interacts with the alpha-Y segment of the
activation helix of the opposite subunit (Figure 5A). The structure
is very similar to that of cofactor-bound PRMT3 (PDB code
2FYT, RMSD: 0.98 A˚), with three important differences: (1) the
inhibitor is partially nested in a pocket which is absent from the
cofactor-bound structure, and located at the base of the dimer-
ization arm (here on referred to as ‘‘the allosteric pocket’’); (2) the
alpha-X segment of the activation helix, that was shown to be
critical for catalytic activity of PRMT1 and CARM1 (Troffer-Char-
lier et al., 2007; Zhang and Cheng, 2003) is disordered; (3) the
cofactor is missing (Figure 5A and Figure S3).
Compound 1 binds to PRMT3 at the dimer interface. Three
structural features characterize the interaction: First, the benzo-
thiadiazole moiety fits tightly in the allosteric pocket, and forms
a hydrogen bond with the side chain of T466. Second, the urea
linker is located at the entrance of the cavity, and forms hydrogen
bondswith the guanidiniumof R396 and the carboxylate of E422.
Third, the cyclohexyl arm extends out of the allosteric pocket
and makes hydrophobic interactions with a surface composed
of the side chains of R396 and E248 from two different mono-
mers (Figure 5B).
Importantly, in the structure of the same PRMT3 construct
bound to SAH, the side chain of R396 interacted with E422 of
the same subunit, resulting in complete obstruction of the
allosteric pocket (PDB code 2FYT) (Figure 5B; left panel).
Compound 1 binding induces flipping of R396 out of the pocket.
This motion is accompanied by a structural rearrangement of
Y244 of the alpha-Y segment of the activation helix, and loss
of electron density for the alpha-X segment, which apparently
becomes disordered (Figures 5B and 5C). It is not clear from
our data whether ligand binding and apparent destabilization
of alpha-X are linked or fortuitous, but we note that (1) the
necessary flipping of R396 is not compatible with the confor-
mation of Y244 observed in the cofactor-bound structure (PDB
code 2FYT), (2) Y244 is positioned at the junction of alpha-X
and alpha-Y segments, and (3) proper folding of alpha-X onto
the cofactor is required for the enzymatic activity of PRMT1
and CARM1 (Troffer-Charlier et al., 2007; Zhang and Cheng,
2003). Analytical ultracentrifugation data indicated that PRMT3
is a dimer in solution in the presence and absence of the
compound (Supplemental Experimental Procedures).
Site-Directed Mutagenesis
To investigate the mechanism of inhibition of PRMT3 by
compound 1, we mutated residues involved in compound
binding (K392, V420, E422, and T466) and dimerization (W400)
(Table 2). We also mutated R396, which is involved in both
compound binding and dimerization in the inhibitor-bound
conformation, but not in the cofactor-bound form. In order to
distinguish mutations that globally destabilized the protein, we
measured the thermal stability and in vitro half-life of each
mutant. Mutation of R396, W400, E422, and T466 all had global
effects on protein stability, indicating the importance of both
dimerization and residues of the allosteric pocket to the overall
fold and activity of PRMT3. The other three mutants had–1435, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1427
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Figure 3. Kinetic Analysis of Compound 1 Inhibition of PRMT3 Activity
Lineweaver-Burk plots for kinetic analysis of compound 1 inhibition by SAHH-coupled assay at varying concentrations of (A) SAM and (B) H4 (1–24) peptide are
shown at 0 (C), 1.5 (B), 3 (;), and 6 (7) mM of compound 1.
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An Allosteric Inhibitor of PRMT3interesting activities that support our analysis of the mode of
action of compound 1. The V420W mutant was designed to
mimic the action of the inhibitor by occupying the allosteric
pocket and forcing R396 to flip out of the pocket (Figures 5B
and 5D). This mutant had significantly reduced catalytic effi-
ciency (5,400 versus 65,400 M1 min1) and increased the IC50
value for the compound by an order of magnitude (Table 2; Fig-
ure 6). Second, mutation of K392 to either Arg or Ala would be
expected to antagonize the binding of compound 1 by recruiting
E422 away from the inhibitor or opening the binding pocket to
solvent, respectively (Figure 5D). Indeed compound 1 displayed
approximately 5-fold weaker inhibition with these two mutants
compared to wild-type protein (Table 2; Figure 6). These results
show that mutants mimicking the action of compound 1 at the
allosteric site inhibit PRMT3, and mutants preventing compound
1 from binding at the allosteric site neutralize the compound’s
ability to inhibit the enzyme.
Several lines of evidence clearly indicate that the confor-
mation of helix alpha-X controls the enzymatic activity of
PRMTs. First, alpha-X folds like a lid on the cofactor (Figure 5C
and Figure S3), which allows interaction between a conserved
tyrosine of the helix with a catalytic glutamate (Y241 and E355
in PRMT3, respectively), in a conformation necessary for proper
positioning of the substrate arginine (Troffer-Charlier et al., 2007;
Yue et al., 2007). A very specific positioning of alpha-X is there-
fore necessary for the formation of a catalytically competent
active site. Second, alpha-X is disordered in all PRMT structures
where the cofactor is missing while it is folded on the cofactor
in structures of CARM1 and PRMT3 almost in all structures
where the cofactor is present (Figure S3) (Troffer-Charlier et al.,
2007; Yue et al., 2007; Zhang et al., 2000). Third, deletion of
alpha-X from rat PRMT1 reduced cofactor binding and abolished
enzymatic activity (Zhang and Cheng, 2003). We have shown
that binding of compound 1 induces conformational side-chain
rearrangements at the junction of alpha-Y and alpha-X helices
and is accompanied by destabilization of helix alpha-X (Figures
5B and 5C). It is possible that this chain of events is causative
and underlies the mechanism of allosteric inhibition. It is also1428 Structure 20, 1425–1435, August 8, 2012 ª2012 Elsevier Ltd Alpossible that binding of compound 1 at the allosteric site
prevents positioning of the substrate peptide in a catalytically
competent conformation.
Structure-Activity Relationship Confirms that Binding at
the Allosteric Site Mediates Inhibition
To further confirm the conformation of compound 1 within the
allosteric binding pocket of PRMT3 and to test the features of
the compound required for binding and inhibition, we carried
out structure-activity relationship (SAR) studies as a complemen-
tary approach to site-directed mutagenesis. We first examined
whether the uncommon cyclohexenylethyl group was absolutely
needed for the inhibitory activity. As expected, this uncommon
group could indeed be replaced by a more common group, the
cyclohexylethyl group, without any potency loss and the alkene
functionality was unnecessary (compound 1 versus compound
2, Table 3). On the other hand, the replacement of the cyclohex-
enylethyl (compound 1) or cyclohexylethyl group (compound 2)
with the benzyl group (compound 5) led to almost 10-fold loss
of potency. We then designed and synthesized the other
compounds outlined in Table 3 to probe hydrogen-bond interac-
tions of compound 1 with the allosteric binding pocket of
PRMT3. Replacing the benzothiadiazole moiety (compound 2)
with the corresponding benzothiazole moiety (compound 3)
resulted in > 50-fold loss of potency, suggesting that the
hydrogen-bond interaction between the middle nitrogen of
benzothiadiazole moiety and T466 is critical for binding. N-meth-
ylation of either nitrogen of the urea moiety led to complete
loss of potency (>50-fold potency loss for compound 4 versus
compound 2; >5-fold potency loss for compound 7 versus
compound 5), which suggests that the hydrogen-bond interac-
tions between the urea moiety and E422 are important. In addi-
tion, compound 6, a thiourea designed to probe the hydrogen-
bond interaction between the oxygen of the urea moiety
and R396, was over 5-fold less potent than its urea analog,
compound 5. These data clearly show that hydrogen-bond
interactions observed in the crystal structures that are key for
binding at the allosteric site are also critical for inhibition. Takenl rights reserved
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Figure 4. PRMT3 Activity Using rpS2 as a Substrate
Km values were determined for (A) rpS2 (1 ± 0.5 mM) and (B) SAM (34 ± 1 mM) with a kcat value of 0.1 min
1 using a radioactivity based assay as described in the
material and method. (C) Activity of PRMT3 was linear at Km of both substrates and (D) was inhibited by compound 1with an IC50 value of 2 ± 0.5 mM. Data points
are presented as mean values ± SD from three experiments.
Structure
An Allosteric Inhibitor of PRMT3together, these results and our mutational analysis strongly
support an allosteric mechanism for PRMT3 inhibition.
Bioavailability of Compound 1
In order to determine cell permeability of compound 1, we con-
ducted Caco2 permeability and efflux assay as described in
the Supplemental Experimental Procedures. This is an in vitro
assay to test for intestinal absorption and efflux of compounds
that can also be used as an indication of cell permeability (Arturs-
son, 1990; Yee, 1997). Compound 1 was tested at 10 and 20 mM
in triplicate along with metroprolol (a positive control with high
permeability and low efflux), atenolol (low permeability) and
digoxin (with low permeability and high efflux). The data for all
controls were reproducible and compound 1 showed high
permeability and negative efflux indicating it is cell permeable
(Table S1). However, unlike the controls, post-assay recovery
of compound 1 was only 32% at 20 mM suggesting the
compound may have been metabolized or precipitated during
the assay period. To assess whether the compound is likely to
be metabolized, it was subjected to a liver microsome assay
(Supplemental Experimental Procedures). Liver microsome
stability is typically used as an in vitro model of first-pass metab-
olism, but we are only using it here as an indicator of metabolic
liability in any cellular system including Caco2 that contains
metabolizing enzymes, such as cytochrome P450s (EngmanStructure 20, 1425et al., 2001; Meyer et al., 2007; Swanson, 2004). Testosterone
and propranolol were used as controls. These compounds are
expected to be significantly metabolized in this system within
30 min. Antipyrine on the other hand is expected to be stable
within the same timeline. All controls worked as expected (Table
S2). Compound 1 was assayed in triplicate using both human
and mouse liver microsomes. The percent remaining for
compound 1 was only about 8% indicating that this compound
may not be stable enough for cell-based assays. Generating
more stable analogs may provide better tools for follow-up
experiments.
DISCUSSION
By screening a diverse library of drug-like compounds, we
have identified compound 1 as a selective PRMT3 inhibitor.
Enzyme kinetics, cocrystal structure of the complex, mutational
analysis, and structure-activity relationship all indicate that
PRMT3 inhibition is mediated by binding at a previously un-
known allosteric site.
Clinical approval of HDAC and DNA methyltransferase inhibi-
tors for treatment of hematological malignancies has resulted
in a growing interest in chemical regulation of chromatin medi-
ated signaling. Consequently, a number of potent and selective
inhibitors targeting PMTs have recently been reported (Yost–1435, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1429
Table 1. Data Collection and Refinement Statistics of the
PRMT3-Compound 1 Cocrystal Structure—Molecular
Replacement
3SMQ
Data Collection
Space group P43212
Cell dimensions
a, b, c (A˚) 70.65, 70.65, 171.98
a, b, g () 90.00, 90.00, 90.00
Resolution (A˚) 50.00–2.00(2.03–2.00)
Rsym or Rmerge 0.078 (0.558)
I / sI 36.61 (2.17)
Completeness (%) 98.1 (83.4)
Redundancy 11.5 (6.0)
Refinement
Resolution (A˚) 50.00–2.00
No. reflections 28,754
Rwork / Rfree 0.190/0.215
No. atoms
Protein 2,374
Ligand/ion 21
Cholide 1
Water 226
B factors
Protein 29.1
Ligand/ion 33.0
Water 41.1
Rmsds
Bond lengths (A˚) 0.010
Bond angles () 1.214
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An Allosteric Inhibitor of PRMT3et al., 2011). For example, new peptide-competitive inhibitors
have been reported for the PKMTs G9a (Vedadi et al., 2011)
and SMYD2 (Ferguson et al., 2011) as well as PRMT CARM1
(Sack et al., 2011), and a cofactor-competitive inhibitor was
recently reported for DOT1L (Daigle et al., 2011). To our knowl-
edge, no allosteric inhibitor has yet been reported for any writer,
reader or eraser of methyl marks. We believe that the discovery
of compound 1 stands as a proof-of-concept for allosteric inhibi-
tion of PRMTs: a pocket is present at the same position in
cofactor-bound PRMT1 (PDB code 1ORI) and a narrow channel
can be seen in apo CARM1 (PDB code 3B3J) that may be able to
accommodate small molecule ligands upon side-chainmotion. It
is therefore reasonable to speculate that the allosteric mecha-
nism described here may apply to PRMTs in general. The struc-
tures of PRMTs are dramatically different from those of PKMTs,
in that PKMTs have an unrelated topology and are active as
monomers. The allosteric site that we have identified has there-
fore no equivalent in PKMTs, and it is highly improbable that
compounds binding at this site would inhibit PKMTs. The allo-
steric mechanism uncovered is therefore PRMT specific.
PRMTs are ubiquitously expressed, essential for embryogen-
esis (Pawlak et al., 2000; Yadav et al., 2003) and regulate gene
expression (Guccione et al., 2007; Hyllus et al., 2007; Iberg1430 Structure 20, 1425–1435, August 8, 2012 ª2012 Elsevier Ltd Alet al., 2008). PRMT3 has been implicated in a variety of biologi-
cal processes including methylation of rpS2, PABPN1, and
interaction with DAL-1/4.1B tumor suppressor. Increase in its
activity or level of expression may also contribute to coronary
heart disease: in normal vascular physiology, endothelium-
derived nitric oxide (NO) is one of the most potent endogenous
vasodilators and is known as an endogenous vasoprotective
agent in diabetes (Colasanti and Suzuki, 2000; Groop et al.,
2005; Mariotto et al., 2004; Yamagishi and Matsui, 2011). NO
is synthesized from L-arginine via the action of NO synthase
(NOS) (Yamagishi and Matsui, 2011). Endogenous L-arginine
analogs such as asymmetric dimethylarginine (ADMA) inhibit
NOS. ADMA is not derived from the methylation of free arginine,
rather it is produced during catabolism of proteins with asym-
metric dimethylated arginine (Kielstein et al., 2001a, 2001b; Val-
lance and Leiper, 2004). Plasma levels of ADMA are elevated in
patients with vascular disease (Kielstein et al., 2001a) and so are
PRMT1 and PRMT3 expression levels in myocardial tissue from
patients with atherosclerosis (Chen et al., 2006), implicating
PRMT3 in regulation of NOS activity and related diseases.
Thus, further optimization of compound 1 should result in the
generation of chemical tools to probe the relevance of PRMT3
as a therapeutic target in vascular and related diseases.
EXPERIMENTAL PROCEDURES
Material
A sixteen thousand diverse, commercial library of drug-like compounds was
screened to identify compound 1 whereas the rest of the compounds were
synthetically prepared (see the Supplemental Experimental Procedures for
details).
Adenosine deaminase (ADA) was purchased from Sigma (Cat. no.
096K7003; http://www.sigmaaldrich.com), ThioGlo from Calbiochem (Cat.
no. 595501; http://www.emdchemicals.com) and SAH (S-adenosine homo-
cysteine) from Sigma (Cat. no. A9384). 384-well plates were purchased from
Axygen (Cat. no. PCR-384-BK; http://www.axygen.com) and Greiner (Cat.
no. 784209; http://www.greinerbioone.com). 96-well plates were obtained
from Nalgene (Cat. no. 249944; http://www.nalgenelabware.com). Histone 4
(H4 [1–24], SGRGKGGKGLGKGGAKRHRKVLRD) and histone 3 (H3 [1–25],
ARTKQTARKSTGGKAPRKQLATKAA) were purchased from Tufts University.
Full-length human, recombinant, N-terminal GST tagged PRMT3 was
purchased from BPS Bioscience (Cat. no. BPS-51043, Lot no. 110111).
Cloning of PRMT3 Mutants
All PRMT3 mutants were generated by site-directed mutagenesis. Primers
that spanned the altered codons with sizes ranging from 29 to 58 bp were
designed using the ‘‘Quikchange Primer Design’’ program (http://www.
genomics.agilent.com). The wild-type PRMT3 gene (amino acids 211–531)
was cloned into the pET28a-LIC vector (GenBank EF442785), expressed
and purified as previously reported (Wu et al., 2010). PRMT3 DNA was
then PCR-amplified using Pfu Ultra II (Stratagene) with the designed primers
according to the manufacturer’s protocol (http://www.genomics.agilent.
com/files/Manual/200523.pdf). The PCR products were digested with DpnI
for 1 hr at 37C, and transformed into DH5a cells. The cells were plated
on Luria broth (LB) plates supplemented with 50 mg/ml kanamycin and
incubated overnight at 37C. Three colonies were chosen from each plate,
inoculated into 3 ml of LB (with kanamycin), and incubated overnight at
37C with shaking. DNA was purified from each cell pellet using the QIAprep
Spin MiniPrep Kit (QIAGEN). All mutations were confirmed by sequencing
(ACGT).
Expression and Purification of PRMT3 Mutants and rpS2
The PRMT3 mutant constructs and rpS2 construct (GST-rpS2; a generous
gift from Dr. Mark Bedford) were expressed in BL21-V2R-pRARE-2 cellsl rights reserved
Figure 5. Structural Analysis of Compound 1 Binding
(A) Overall structure. The PRMT3 catalytic core adopts a canonical PRMT
dimeric structure. The inhibitor (magenta) binds a pocket at the base of the
dimerization arm (cyan) of one chain and contacts the alpha-Y segment of the
activation helix of the other monomer (red). The alpha-X segment of the acti-
vation helix is disordered (dashed line), and the cofactor is absent (blue star:
expected position).
(B) Inhibitor binding. In the absence of inhibitor, R396 occupies the binding
pocket. Helix alpha-X: cyan; helix alpha-Y: green (left). Inhibitor binding
induces consecutive conformational rearrangements of residues at the
N-terminus of helix alpha-Y, accompanied by destabilization of helix alpha-X
(disordered, right). The thiadiazole end of the compound is deeply buried in
Structure
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Structure 20, 1425(SGC Toronto) and purified as described in the Supplemental Experimental
Procedures.
Biochemical Assays
SAHH-Coupled Assay
The methyltransferase activities of G9a, SETD7, PRMT3, EHMT1, SETD8,
SUV39H2, and PRMT3 mutants were measured using SAHH-coupled assay
as described before (Allali-Hassani et al., 2011). In this assay, SAHH and
ADA convert the methyltransferase reaction product SAH to homocysteine
and inosine. The abundance of homocysteine is quantified using ThioGlo (Cal-
biochem), which reacts with thiols and fluoresces strongly (Supplemental
Experimental Procedures).
Scintillation Proximity Assay
Selectivity of compound 1 against PRMT1, PRMT4, PRMT5-MEP50 complex,
and PRMT8 was assessed by a radioactivity based assay in parallel with that
for full-length (FL) PRMT3. The radioactivity based assay was used as these
PRMTs were not amenable to SAHH-coupled assay. In this assay 3H-SAM
(Cat. no. NET155V250UC, Perkin Elmer) was used as a methyl donor to meth-
ylate peptide substrates. Peptide substrates were biotinylated to be captured
in each well through their interaction with streptavidin using a streptavidin-
coated Flash plate. The amount of the product (methylated peptide) was
quantified by tracing the radioactivity (counts per minutes measured by a
TopCount reader from Perkin Elmer). Assay conditions were optimized for
each protein separately, and all experiments were performed at linear initial
velocity. The first 24 residues of histone 4 (H4 [1–24], SGRGKGGKGLGK
GGAKRHRKVLRD) was used as a substrate for PRMT1, PRMT3 (FL),
PRMT5/MEP50, and PRMT8. The substrate for PRMT4 was 24 residues of
histone 3 (H3 [21–44], ATKAARKSAPATGGVKKPHRYRPG). The final concen-
trations of PRMT1, PRMT3 (FL), PRMT4, PRMT5-MEP50 complex, and
PRMT8 in the assay were 20, 350, 270, 500, and 150 nM, respectively. The
concentrations of SAM and peptide substrate were set around their
respective Km values. SAM concentration for PRMT1 and PRMT8 was
10 mM, and for PRMT3 (FL) and PRMT4 was 20 mM. Peptide concentrations
for PRMT1, PRMT3 (FL), PRMT4, and PRMT8 were 15, 7, 20, and 15 mM,
respectively. For PRMT5/MEP50 complex SAM concentration of 6 mM, and
peptide (H4 [1–24]) concentration of 20 mM was used. The reaction was
prepared in the final volume of 10 ml. The reaction mix contained 7 ml of buffer
(20 mM Tris, 10 mM DTT [pH 8]), 1 ml enzyme, and 1 ml of 66 mM 3H-SAM
(diluted with cold SAM to achieve the desired concentrations of SAM in
each assay). The reaction was started by adding 1 ml of a respective peptide
substrate. The reaction mixtures were incubated for 60 min for all HMTs
except for PRMT5/MEP50 complex, for which the reaction was incubated
for 30 min. The reaction was quenched with equal volumes of 7.5 M guani-
dine-HCl. 10 ml of the reaction mix containing Guanidine-HCl was mixed
with 190 ml of 20 mM Tris buffer (pH 8) and transferred into a Flash plate
(96-well FlashPlate, Cat. no. SMP103, Perkin Elmer, http://www.perkinelmer.
com/). The plate was incubated for an hour prior to reading using a TopCount
(Perkin Elmer, http://www.perkinelmer.com/) to accumulate maximum signal.
PRMT3 Activity Assay Using rpS2 as a Substrate
Effect of compound 1 on PRMT3 methylation of its physiological substrate
rpS2 was tested using a radioactivity based assay. In this assay 3H-SAM
(Cat. no. NET155V250UC, Perkin Elmer) was used as a methyl donor to
methylate rpS2 substrate. PRMT3 andmethylated rpS2were later precipitated
using 10% trichloroacetic acid (TCA) and captured on 96-well Multiscreen
Filter Plates (Cat. no. MSFBN6B10, Millipore). The amount of the productthe pocket and is hydrogen bonded to the hydroxyl group of T466; the urea
linker is positioned at the entrance of the pocket and forms hydrogen bonds
with the side chains of R396 and E422; the cyclohexyl moiety extends out of
the pocket, toward the alpha-Y helix of the second monomer (red).
(C) Proposed inhibition mechanism. Compound 1 binding (magenta) induces
a conformational rearrangement at the N-terminus of helix alpha-Y (inhibitor
present: red, inhibitor absent: green), which destabilizes the active form of
helix alpha-X (cyan), critical for enzymatic activity.
(D) Mapping of critical residues at the allosteric site.
See also Figure S3 and Table S1.
–1435, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1431
Table 2. Characterization of PRMT3 Mutants
Protein
Km (mM)
kcat (min
1) 3 102 kcat/ Km (M
1 min1) Compound 1 IC50 (mM) t1/2 (min)Peptide SAM
Wild-type 13 ± 4 20 ± 2 85 ± 10 65400 2.2 ± 0.1 >300
K392R 16 ± 2 19 ± 7 127 ± 10 79400 12 ± 1 >300
K392A 12 ± 2 21 ± 3 52 ± 7 43300 9.1 ± 0.4 >300
V420W 33 ± 0.4 33 ± 10 18 ± 7 5400 23 ± 1 >300
E422A Not stable Not stable Not stable Not stable NA >300
T466A Not stable Not stable Not stable Not stable NA 36 ± 6
T466V Inactive Inactive Inactive Inactive NA 38 ± 1
R396N Inactive Inactive Inactive Inactive NA 44 ± 10
R396E Inactive Inactive Inactive Inactive NA 24 ± 3
W400D Inactive Inactive Inactive Inactive NA 20 ± 2
Structure
An Allosteric Inhibitor of PRMT3(methylated rpS2) was quantified by tracing the radioactivity (counts per
minute measured by a TopCount reader from Perkin Elmer). Assay conditions
were optimized so that the experiment was performed at linear initial velocity.
PRMT3, rpS2 and SAM concentrations were 500 nM, 1 mM, and 50 mM,
respectively. The reaction was prepared in the final volume of 20 ml. The reac-
tion mixture contained 14 ml of buffer (20 mM Tris, 10 mM DTT [pH 8]), 2 ml
enzyme, and 2 ml of 66 mM 3H-SAM (diluted with cold SAM to achieve the
desired SAM concentration). The reaction was started by adding 2 ml of
rpS2 substrate. The reaction mixtures were incubated for 45 min and
quenched with 80 ml 10% TCA. One hundred microliters of the reaction mix
containing TCA was transferred into a filter plate (96-well Multiscreen Filter
Plates from Millipor). The plate was washed twice with 80 ml 10% TCA and
once with ethanol. After ethanol evaporated, 50 ml of scintillation liquid was
added and radioactivity was measured using a TopCount (Perkin Elmer).
Crystallization
PRMT3 was incubated at 1.1 mg/ml overnight with compound 1 at 1:30 molar
ratio (PRMT3: compound 1). Following incubation, protein was concentrated
to 3 mg/ml and crystallized using the sitting drop diffusion method at 20C
by mixing 1 ml of the protein solution with 1 ml of the reservoir solution contain-
ing 20%PEG 4K, 0.2MMgOAc, 0.1MNaCaco (pH 6.5). Prior to freezing, 0.1 mlCompound 1 (µM)
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1432 Structure 20, 1425–1435, August 8, 2012 ª2012 Elsevier Ltd Alof 100 mM compound 1was added directly to the drop. Crystals were soaked
for 30 min in the same buffer with 10% glycerol.
Data Collection and Processing
The native data set was collected on CLS beamline CMCF-ID at 100 K.
Program HKL2000 was used for data processing and scaling (Minor et al.,
2006).
Structure Determination and Refinement
PRMT3 structure in complex with compound 1 was determined using the
molecular replacement method with the 2FYT structure as a model. Graphic
programCOOTwas used for manual model refinement and visualization (Ems-
ley and Cowtan, 2004). Refmac5 were used to refine the model (Murshudov
et al., 1997). MolProbity was used to validate the refined structure (Chen
et al., 2010). Ninety eight percent of residues are in the favored regions of
Ramachandran plot and none of them in the disallowed regions. The structure
has been deposited in the RCSB with PDB code 3SMQ.
SPR Experiments
SPR experimentswere performed at 25Cusing aGEHealthcare Biacore T200
instrument (http://www.biacore.com). 6xHis-tagged PRMT3 protein (20 mg/ml001
Figure 6. Effect of Compound 1 onActivity of
PRMT3 Variants
IC50 values were determined at balanced condi-
tions using SAHH-coupled assay for wild-type
PRMT3 (C), K392R (B), E422A (;), V420W (6),
and K392A (-). E422A was only active when
freshly made and lost activity quickly, making it
difficult to determine its kinetic parameters repro-
ducibly. Therefore the experiments for this mutant
were performed at estimated Km of substrates
(3 mM of peptide and 50 mM of SAM) for compar-
ison. Data points are presented as mean values ±
SD from three experiments.
l rights reserved
Table 3. SAR of the Compounds Designed to Probe Hydrogen-
Bond Interactions of Compound 1 with the Allosteric Binding
Pocket of PRMT3
Structure
An Allosteric Inhibitor of PRMT3in 10 mM sodium acetate [pH 5.0]) was amine-coupled to a CM5 chip using
the GE Healthcare amine coupling kit (BR-1000-50) and the manufacturer’s
standard protocol (5779 RU immobilized). All small molecule analysis experi-
ments were performed in HBS-EP running buffer (10 mM HEPES [pH 7.4],
150 mM NaCl, 3 mM EDTA, 0.05% Tween-20) supplemented with 5%
DMSO. The PRMT3–compound 1 affinity determination was performed in
duplicate using single cycle kinetics with a 5 point, 2-fold serial dilution from
20 mM down to 1.25 mM. A flow rate of 30 ml/minute was used with on and
off times of 60 s each. A DMSO calibration curve was used for data correction.
KD values were calculated using the Biacore BiaEvaluation software (GE
Healthcare).
Isothermal Aggregation
Half-life of all mutants and the wild-type were determined using isothermal
aggregation as described before (Hong et al., 2010) (Supplemental Experi-
mental Procedures).
Compound Quality Control
Compounds ordered from vendors were evaluated for purity by LC/MSwith an
acceptable purity standard set at R85% by UV (254 nm). Purity (along with
compound identity) was further confirmed by nuclear magnetic resonance
spectroscopy (500 MHz), and compounds failing to meet the standard were
subsequently purified by silica gel column chromatography prior to further
assessment.
Chemical Synthesis
Synthetic procedures and chemical characterization of compounds 1, 2, 3, 4,
5, 6, and 7 are detailed in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.str.2012.06.001.
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